Updates in precision medicine for prostate cancer

Andrew Laccetti, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the latest developments in precision medicine for prostate cancer. Due to the heterogeneity of prostate cancer, next-generation sequencing (NGS) is vital to differentiate the different types of tumors. PARP inhibitors are particularly effective in BRCA-mutant prostate cancer and genetic testing can identify patients with tumor mutational burden (TMB) and MSI high tumors who will benefit from checkpoint inhibitors. Genetic testing can additionally identify certain genes associated with more aggressive prostate cancer such as RB1 and PTEN. Dr Laccetti also highlights targeted therapies such as radioligands and antibody-drug conjugates. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.